Literature DB >> 16112499

The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus.

Ender Arikan1, Tevfik Sabuncu, Esref M Ozer, Husrev Hatemi.   

Abstract

It has been reported that some patients with Type 2 diabetes mellitus (DM) have latent autoimmune diabetes in adults (LADA) and may show different clinical characteristics than those with Type 2 DM. We aimed to determine the ratio and clinical features of LADA in patients with diagnosed initially as Type 2 DM. We measured glutamic acid decarboxylase antibodies (GADA) in 54 patients, diagnosed clinically with Type 2 DM. Of 54 patients, 17 (31%) were GADA positive. GADA-positive patients had significantly earlier diabetes onset age (P<.001), lower BMI (P<.05), and lower serum C-peptide value (P<.001) than did those who were GADA negative. A higher proportion of the GADA-positive patients were receiving insulin therapy (P<.01). With respect to the duration of DM, familial history of DM, and the levels of blood pressures, fasting plasma glucose, and HbA1c, there was no difference between the two groups. Nephropathy and retinopathy were more frequent in GADA-positive than in GADA-negative patients. The prevalence of neuropathy was comparable between the two groups. GADA was negatively associated with BMI, C-peptide levels, and diabetes-onset age, but positively related to retinopathy, nephropathy, and insulin treatment. This study indicated that the important portion of the patients who were initially diagnosed as Type 2 DM may have LADA. In Type 2 diabetic patients who have lower BMI and diagnosis of diabetes in relatively younger age, the possibility of LADA should be taken into consideration. The higher prevalence of nephropathy and retinopathy in GADA-positive patients also suggests the importance of early diagnosis and strict metabolic control in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112499     DOI: 10.1016/j.jdiacomp.2005.02.004

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

Review 1.  Diagnostic criteria of latent autoimmune diabetes in adults (LADA): a review and reflection.

Authors:  Yu Liao; Yufei Xiang; Zhiguang Zhou
Journal:  Front Med       Date:  2012-07-28       Impact factor: 4.592

Review 2.  Adult-onset autoimmune diabetes: current knowledge and implications for management.

Authors:  Raffaella Buzzetti; Simona Zampetti; Ernesto Maddaloni
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

3.  Association of cytotoxic T lymphocyte-associated antigen 4 gene single nucleotide polymorphism with type 1 diabetes mellitus in Madurai population of Southern India.

Authors:  Beatrice Philip; W Isabel
Journal:  Indian J Hum Genet       Date:  2011-05

Review 4.  A Practical Review of C-Peptide Testing in Diabetes.

Authors:  Emma Leighton; Christopher Ar Sainsbury; Gregory C Jones
Journal:  Diabetes Ther       Date:  2017-05-08       Impact factor: 2.945

5.  The prevalence and characteristics of latent autoimmune diabetes in adults subset among type two diabetes mellitus patients in Northern Nigeria.

Authors:  Salisu Babura Muazu; Innocent Okpe; Felicia Anumah
Journal:  Ann Afr Med       Date:  2016 Oct-Dec

Review 6.  Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.

Authors:  Paolo Pozzilli; Silvia Pieralice
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

7.  Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis.

Authors:  Elias S Siraj; Carol Homko; Laura A Wilson; Patrick May; Ajay D Rao; Jorge Calles; Gianrico Farrugia; William L Hasler; Kenneth L Koch; Linda Nguyen; William J Snape; Thomas L Abell; Irene Sarosiek; Richard W McCallum; Pankaj J Pasricha; John Clarke; James Tonascia; Frank Hamilton; Henry P Parkman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-13       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.